bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
LBCHAMIK

Order Name:
Amikacin

 
Useful For:
Intended for the quantitative determination of amikacin in human serum or plasma. The results obtained are used in the diagnosis and treatment of amikacin overdose and in monitoring levels of amikacin to help ensure appropriate therapy.
 
Methodology:
Particle-enhanced turbidimetric inhibition Immunoassay (PETINIA)
 
AliasesName:
Amikin
 
 
 
Test Code:
LBCHAMIK

Order Name:
Amikacin

 
Patient Preparation:
Follow the instruction of physician and pharmarcist.
 
Collection Specimen Or Container:
Blood/ Plain blood (Red top) 6 mL, 1 tube
 
Specimen Testing Type:
Serum, minimum volume 0.5 mL
 
Sub Mission Container:
Plastic vial
 
Rejection Criteria:
Hemolysis: Mild reject
Lipemia: 4+ reject
Icterus: 3+ reject
Other: N/A
 
Specimen Stabillity:
Specimen Type Temperature Time
Serum Refrigerated, 2oC to 8oC 7 days
Serum Frozen, -20oC 14 days
 
 
 
Test Code:
LBCHAMIK

Order Name:
Amikacin

 
Method detail:
Particle-enhanced turbidimetric inhibition Immunoassay (PETINIA)
 
Schedule:
Tested daily (24 Hours)
 
Turnaround Time:
Collected specimen to report within 1.5 hours (90 mins)
 
Performing Location:
Chemistry, Laboratory Department Tel. 13224
 
Specimen Retention Time:
5 days
 
 
 
Test Code:
LBCHAMIK

Order Name:
Amikacin

 
 
Clinical Information:
Amikacin is a semi-synthetic aminoglycoside that exhibits bactericidal activity against a wide range of pathogens, including many organisms resistant to other aminoglycosides. Amikacin is active in vitro against gram-negative organisms, penicillinase, and non-penicillinase producing staphylococci. The strength of this drug is due primarily to its high degree of resistance to aminoglycoside-inactivating enzymes. Determination of serum or plasma drug levels is required to achieve optimum therapeutic efficacy and minimize toxicity.
 
Reference Value:
Peak values: 25-35 µg/mL
Trough values: 4-8 µg/mL
 
Interpretation:
Although optimum values may vary, periodic measurements of both peak and trough concentrations of amikacin are recommended to ensure adequate drug levels and prevent toxic side effects.  The most serious toxic effect is permanent damage to the vestibular division of the eighth cranial nerve, which has been reported to occur most frequently in patients with renal failure. Amikacin is inherently stable, is not metabolized, and is excreted primarily by glomerular filtration.

Therefore, the presence of renal impairment drastically alters its pharmacokinetics. If dosage regimens are not drastically adjusted, excess accumulation leading to ototoxicity and further renal impairment could be encountered. While elevated serum levels can be toxic, indiscriminately low dosages of amikacin will result in ineffective treatment for many strains of gram-negative bacteria. Organisms which are resistant to amikacin will often show increased resistance to all other available aminoglycosides. This observation points out the possibility that the indiscriminate use of low dosages of amikacin could engender the emergence of drug-resistant organisms and possibly render the drug ineffective in treating infectious disease.  

Each laboratory should investigate the transferability of the expected values to its own patient population and, if necessary, determine its own therapeutic range.
 
Clinical Reference:
  1. Manufacturer’s reagent package insert, Architect Amikacin,  Microgenics Corporation, 46500 Kato Road, Fremont, CA 94538, USA, October 2016.
  2. Reference of reference intervals: UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com (Retrieved: July 2018)
  3. http://www.mayomedicallaboratories.com (Retrieved: 01 Jan 2019)